Compare DNUT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | MYGN |
|---|---|---|
| Founded | 1937 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.2M | 481.6M |
| IPO Year | 2021 | 1996 |
| Metric | DNUT | MYGN |
|---|---|---|
| Price | $3.35 | $4.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $4.72 | ★ $7.64 |
| AVG Volume (30 Days) | ★ 2.4M | 1.8M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,522,616,000.00 | $771,400,000.00 |
| Revenue This Year | $0.48 | $7.19 |
| Revenue Next Year | $3.33 | $5.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $2.58 | $3.76 |
| 52 Week High | $5.73 | $9.48 |
| Indicator | DNUT | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 44.59 |
| Support Level | $3.05 | $4.24 |
| Resistance Level | $3.48 | $5.69 |
| Average True Range (ATR) | 0.17 | 0.32 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 31.30 | 32.04 |
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.